Target intelligence / Profile preview

Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1)

Target
GABRA1
Molecular classification
Ion channel, Ligand-gated ion channel, Cys-loop receptor, Receptor
01

Overview

The Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1) is a key component of the GABAA receptor, the primary mediator of rapid inhibitory neurotransmission in the central nervous system (UniProt: P14867). This subunit typically assembles with beta and gamma subunits to form a pentameric chloride channel, with the alpha-1/beta-2/gamma-2 configuration being the most prevalent in the brain. The benzodiazepine binding site is a distinct allosteric pocket located at the interface of the alpha-1 and gamma-2 subunits. Binding of positive allosteric modulators, such as benzodiazepines and Z-drugs, increases the frequency of channel opening in response to GABA, leading to enhanced chloride influx and neuronal hyperpolarization (StatPearls: NBK513311).

Pharmacologically, the alpha-1 subunit is specifically associated with the sedative, hypnotic, and anticonvulsant effects of benzodiazepine-site ligands, whereas other alpha subunits (alpha-2, alpha-3, alpha-5) mediate anxiolytic and muscle-relaxant effects. Consequently, alpha-1 selective agents like zolpidem are widely used for the treatment of insomnia. Beyond its role as a drug target, mutations in the GABRA1 gene are linked to various idiopathic generalized epilepsies, highlighting its fundamental role in maintaining the brain's excitatory-inhibitory balance (NCBI Gene: 2554). Therapeutic challenges include the risk of sedation, motor impairment, and the potential for development of tolerance and dependence with chronic use.

Other names
GABAA receptor subunit alpha-1Benzodiazepine receptor 1BZ1Omega-1 receptorGABA(A) receptor alpha-1
02

Mechanism of action

Positive allosteric modulation of the GABA-induced chloride current at the alpha-1/gamma-2 subunit interface

03

Biological functions

Inhibitory neurotransmissionChloride ion transportNeuronal hyperpolarizationSedationHypnosisAnticonvulsant activity
04

Disease associations

InsomniaEpilepsyAnxietyAlcohol use disorderStatus epilepticus
05

Safety considerations

SedationMotor impairmentCognitive impairmentAnterograde amnesiaDependenceToleranceWithdrawal symptoms
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

Electroencephalography (EEG) beta power[11C]flumazenil PET imagingSaccadic eye movement velocity

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call